Where we are: The Footsie is grinding higher toward the 8,230 level as the London session progresses, clawing back some of the losses that have left the index down 0.5% on the week. This intraday bid follows a constructive morning cash session where early seller exhaustion near the 8,180 support zone triggered a steady rotation into defensive heavyweights. While the index is off its weekly highs, it sits comfortably above yesterday’s NY close, establishing a short-term base ahead of the Wall Street open. The intraday range remains bounded by 8,180 on the downside and the 100-day moving average near 8,280 on the upside.
What’s driving it: Domestic macro is dictating today’s price action, led by a stellar UK retail sales print of 1.2% m/m at 07:00 London that handily beat the 0.5% forecast, signaling that consumer demand remains highly resilient despite the Bank of England keeping the Bank Rate restrictive at 3.75% yesterday. This consumer resilience is clashing with regulatory headwinds after the PRA’s 06:00 London consultation on Basel 3.1 market risk internal models, a development that is actively depressing the heavyweight banking sector with Lloyds falling 1.8% and Barclays shedding 0.9%. This banking drag is being partially offset by a defensive rotation into pharma giants AstraZeneca (+1.6%) and GSK (+0.9%), while a modest recovery in WTI crude to $84.65 is providing a secondary lift to BP and Shell. The broader market remains sensitive to the domestic inflation profile after core CPI ticked up to 2.6% YoY, keeping pressure on the gilt curve and capping any unchecked equity multiple expansion.
- The Bank of England’s hold at 3.75% coupled with core CPI ticking up to 2.6% YoY keeps the domestic yield curve flatter, limiting the near-term valuation upside for interest-rate-sensitive domestic equities.
- Today’s retail sales rebound to 1.2% m/m provides a fundamental cushion for domestic consumer discretionary names, helping the index absorb the fiscal drag of May’s £23.3 billion public sector borrowing print.
- The PRA’s Basel 3.1 internal model adjustments are driving a stark intraday sector divergence; UK lenders are underperforming European peers as traders price in more stringent market risk capital charges, making FTSE banks a tactical funding leg for defensive pharma longs.
NY session focus: As we head into the New York session, all eyes are on the US 08:30 ET macro prints, where any downside surprise in US yields from the current 4.49% level on the 10-year could spark a broader global risk-on rally. We like playing the FTSE defensively here, staying long AstraZeneca and GSK while fading banking rallies as the market digests the PRA’s regulatory tightening. A break above 8,250 would open the door to a test of the 100-day moving average at 8,280, whereas a hawkish US data print will likely push the index back down to test the 8,180 support. The absolute pain trade is a massive short-squeeze above 8,300 driven by a sudden collapse in global bond yields and the VIX sliding back below 18.